ABBV * Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3,019.98 |
52 Week High | US$3,070.53 |
52 Week Low | US$2,250.80 |
Beta | 0.56 |
1 Month Change | -1.14% |
3 Month Change | 15.58% |
1 Year Change | 4.86% |
3 Year Change | 41.78% |
5 Year Change | 91.50% |
Change since IPO | 546.48% |
Recent News & Updates
Recent updates
Shareholder Returns
ABBV * | MX Biotechs | MX Market | |
---|---|---|---|
7D | -0.2% | 0% | 0% |
1Y | 4.9% | 0% | 0% |
Return vs Industry: ABBV * exceeded the MX Biotechs industry which returned 2.9% over the past year.
Return vs Market: ABBV * matched the MX Market which returned 4.9% over the past year.
Price Volatility
ABBV * volatility | |
---|---|
ABBV * Average Weekly Movement | 2.7% |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: ABBV * has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV *'s weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | https://www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV * fundamental statistics | |
---|---|
Market cap | Mex$5.27t |
Earnings (TTM) | Mex$80.30b |
Revenue (TTM) | Mex$904.88b |
65.8x
P/E Ratio5.8x
P/S RatioIs ABBV * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV * income statement (TTM) | |
---|---|
Revenue | US$54.32b |
Cost of Revenue | US$16.73b |
Gross Profit | US$37.59b |
Other Expenses | US$32.77b |
Earnings | US$4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.72 |
Gross Margin | 69.21% |
Net Profit Margin | 8.87% |
Debt/Equity Ratio | 573.6% |
How did ABBV * perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield220%
Payout RatioDoes ABBV * pay a reliable dividends?
See ABBV * dividend history and benchmarksAbbVie dividend dates | |
---|---|
Ex Dividend Date | Apr 12 2024 |
Dividend Pay Date | May 15 2024 |
Days until Ex dividend | 16 days |
Days until Dividend pay date | 49 days |
Does ABBV * pay a reliable dividends?
See ABBV * dividend history and benchmarks